Investor Centre Archive - Alterity Therapeutics

Quarterly Cash Flow Report

April 29, 2021May 5, 2021

Highlights: Michael J. Fox Foundation grants Alterity $US495K for Parkinson’s disease research evaluation Strengthening profile at investm

ATH434 protects brain cells and improves motor function

April 21, 2021May 5, 2021

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced an oral presentation of expanded animal

Alterity CEO David Stamler presents to US investors at the HC Wainwright Global Life Science Conference

March 10, 2021May 5, 2021

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) CEO Dr David Stamler is presenting to US investors this

Alterity to present at the 7th International Congress of Multiple System Atrophy

February 26, 2021February 26, 2021

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), will present at the upcoming 7th International

Alterity Half Year Results and Investor Webcast Notification

February 19, 2021February 19, 2021

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), today advises it will release its financial re

Alterity announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson’s disease clinical trials

February 9, 2021February 9, 2021

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the award of a grant from The Micha

Quarterly Cash Flow Report

January 29, 2021January 29, 2021

Highlights: Dr David Stamler appointed CEO; Geoffrey Kempler continues as Non-Executive Chairman New commercial opportunity for PBT2 with Un

New hope in global fight against antibiotic resistant superbugs

January 22, 2021January 22, 2021

New hope in global fight against antibiotic resistant superbugs

Alterity participates in world’s largest virtual healthcare conference JP Morgan

January 11, 2021January 11, 2021

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) CEO Dr David Stamler will meet with investors during th

Dr David Stamler appointed CEO

January 7, 2021January 7, 2021

The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is pleased to announce the appointment of

Alterity and UniQuest to reverse bacterial resistance to antibiotics

December 21, 2020December 21, 2020

New commercial opportunity for PBT2 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced

Alterity presents at Finance News Network investor event

December 2, 2020December 2, 2020

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) CEO and Chairman Mr Geoffrey Kempler will present to in

AGM 2020 Presentation

November 18, 2020November 18, 2020

AGM 2020 Presentation

Chairman’s Address to Shareholders 2020 Annual General Meeting

November 18, 2020November 18, 2020

Chairman’s Address to Shareholders 2020 AGM

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

November 16, 2020November 16, 2020

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the allowance of a new composition

Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study

October 27, 2020May 5, 2021

Alterity Therapeutics today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study in the Uni

Alterity completes Placement Tranche 1 raising $10M

October 23, 2020October 27, 2020

$25M Second Tranche to complete following shareholder approval Alterity completes Tranche 1 of Placement raising $10M Tranche 2 completes on

Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.

October 16, 2020October 16, 2020

Successfully obtained binding commitments for A$35M via institutional placement to be settled in 2 tranches Tranche 1: $10M raised under Alt

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

August 4, 2020August 4, 2020

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that new clinical and experimental phar

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434

June 30, 2020July 1, 2020

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is pleased to announce that it has received guidance fr

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology

May 21, 2020May 21, 2020

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has presented data on ATH434 (formerly PBT434) for the

Alterity receives a $4.8 million R&D Tax Incentive Refund

January 15, 2020January 15, 2020

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced that it has received a A$4.

European Commission approves Orphan Designation for Alterity’s lead drug candidate

January 14, 2020January 15, 2020

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) announces that the European Commission (EC) has

Alterity presents clinical data on PBT434 at the 2019 MDS Congress

September 25, 2019October 10, 2019

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), presents a poster today titled: A First in Hum

Alterity Therapeutics to Present at the Janney Healthcare Conference in New York

September 9, 2019September 9, 2019

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is participating in the Janney Healthcare Confe

Quarterly Cash Flow Report

August 1, 2019August 1, 2019

Highlights: Completion of Phase 1 Clinical Trial; PBT434 found to be safe and well-tolerated; clinically tested doses achieve concentrations

Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial

July 29, 2019July 29, 2019

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that it has successfully comple

Alterity Therapeutics talks to Finance News Network

July 9, 2019July 9, 2019

Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, discusses the company’s development pipeline and lead drug

March 10, 2021	HC Wainwright Global Life Science Conference Presentation – March 2021	pdf	2 MB
December 2, 2020	Alterity Therapeutics FNN presentation – December 2020	pdf	429 KB
November 18, 2020	AGM Presentation 2020	pdf	2 MB
May 22, 2020	Alterity Therapeutics AAN Presentation – May 2020	pdf	402 KB
November 26, 2019	AGM Presentation 2019	pdf	777 KB
June 4, 2019	Alterity Therapeutics Investor Presentation for FNN	pdf	1 MB
May 9, 2019	Alterity Therapeutics AAN Presentation	pdf	755 KB
April 10, 2019	Alterity Therapeutics Investor Presentation	pdf	2 MB
January 8, 2018	Prana Biotechnology JPM investor presentation	pdf	3 MB
January 8, 2018	Biotech Showcase Presentation	pdf	3 MB
January 8, 2018	Biotechnology Biotech Showcase Investor Presentation	pdf	3 MB
April 22, 2016	World Orphan Drug Congress Presentation	pdf	3 MB
July 17, 2014	AAIC Panel Presentation – Colin Masters	pdf	3 MB
February 18, 2014	Reach2HD Clinical Results Investor Presentation	pdf	1 MB

September 9, 2020	Appendix 4G and 2020 Corporate Governance Statement – 9 September 2020	pdf	374 KB
December 31, 2020	Notice of change of interests of substantial holder – 29 December 2020	pdf	820 KB
December 24, 2020	Form F-3 – 24 December 2020	pdf	300 KB
December 21, 2020	New commercial opportunity for PBT2 – 21 December 2020	pdf	283 KB
December 18, 2020	Notice of change of interests of substantial holder – 18 December 2020	pdf	586 KB
December 17, 2020	Form 6-K – 17 December 2020	pdf	237 KB
December 17, 2020	Prospectus Supplement – 17 December 2020	pdf	664 KB
December 10, 2020	Notice of change of interests of substantial holder – 10 December 2020	pdf	820 KB
December 7, 2020	Notice of change of interests of substantial holder – 4 December 2020	pdf	814 KB
December 3, 2020	Form S-8 – 3 December 2020	pdf	171 KB
December 2, 2020	Alterity presents at Finance News Network – 2 December 2020	pdf	653 KB
December 1, 2020	Notice of change of interests of substantial holder (Life Bio) – 1 December 2020	pdf	965 KB
December 1, 2020	Notice of change of interests of substantial holder – 1 December 2020	pdf	586 KB
November 29, 2020	Notice of change of interests of substantial holder (BNYMC) – 25 November 2020	pdf	585 KB
November 29, 2020	Notice of change of interests of substantial holder – 26 November 2020	pdf	152 KB
November 29, 2020	Notice of initial substantial holder – 26 November 2020	pdf	84 KB
November 25, 2020	Notice of change of interests of substantial holder – 25 November 2020	pdf	585 KB
November 24, 2020	Prospectus filed pursuant to SEC Rule 424(b)(3) – 24 November 2020	pdf	261 KB
November 24, 2020	Appendix 3G – 24 November 2020	pdf	345 KB
November 24, 2020	Appendix 2A – 24 November 2020	pdf	377 KB
November 24, 2020	Notice of change of interests of substantial holder – 24 November 2020	pdf	152 KB
November 23, 2020	Notice of change of interests of substantial holder – 23 November 2020	pdf	653 KB
November 19, 2020	Notice of change of interests of substantial holder – 18 November 2020	pdf	587 KB
November 18, 2020	Alterity Therapeutics Constitution (Amended) – 18 November 2020	pdf	433 KB
November 18, 2020	Results of 2020 AGM – 18 November 2020	pdf	191 KB
November 18, 2020	Chairman’s Address to Shareholders 2020 AGM – 18 November 2020	pdf	211 KB
November 18, 2020	AGM 2020 Presentation – 18 November 2020	pdf	2 MB
November 17, 2020	Ceasing to be a substantial holder – 16 November 2020	pdf	453 KB
November 16, 2020	Form F-3 – 16 November 2020	pdf	476 KB
November 16, 2020	Notice of ceasing to be a substantial holder – 16 November 2020	pdf	236 KB
November 16, 2020	US patent for next generation neurodegenerative diseases – 16 November 2020	pdf	181 KB
November 13, 2020	Notice of initial substantial holder – 13 November 2020	pdf	428 KB
October 30, 2020	Appendix 4C- Q1 FY21 Quarterly Cash Flow Report – 30 October 2020	pdf	354 KB
October 27, 2020	Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study – 27 October 2020	pdf	184 KB
October 27, 2020	Notice of change of interests of substantial holder – 27 October 2020	pdf	588 KB
October 26, 2020	Notice of change of interests of substantial holder – 26 October 2020	pdf	2 MB
October 23, 2020	Alterity completes Placement Tranche 1 raising $10M – 23 October 2020	pdf	206 KB
October 23, 2020	Appendix 2A and Section 708A Cleansing Notice – 23 October 2020	pdf	369 KB
October 20, 2020	Notice of Annual General Meeting 2020	pdf	706 KB
October 16, 2020	Proposed issue of securities – ATH – 16 October 2020	pdf	32 KB
October 16, 2020	Proposed issue of securities – ATH – 16 October 2020	pdf	29 KB
October 16, 2020	Alterity raises $35M in placement to institutional investors – 16 October 2020	pdf	235 KB
October 12, 2020	Trading Halt – 12 October 2020	pdf	165 KB
October 6, 2020	Form F-3 – 6 October 2020	pdf	295 KB
September 24, 2020	Form S-8 – 24 September 2020	pdf	126 KB
September 22, 2020	Change of Directors Interest Notice x5 – 21 September 2020	pdf	341 KB
September 21, 2020	Appendix 3G – 18 September 2020	pdf	352 KB
September 16, 2020	Form 20-F 2020	pdf	2 MB
September 16, 2020	Alterity filed Form 20-F and XBRL data with SEC September 2020	pdf	176 KB
September 16, 2020	Annual Report 2020	pdf	2 MB
September 9, 2020	Update on 2020 Annual Report – 9 September 2020	pdf	178 KB
September 4, 2020	Results of General Meeting – 3 September 2020	pdf	170 KB
August 31, 2020	Appendix 4E Year ended 30 June 2020	pdf	454 KB
August 17, 2020	Notice of change of interests of substantial holder – 17 August 2020	pdf	586 KB
August 3, 2020	Notice of General Meeting and Explanatory Memorandum – August 2020	pdf	591 KB
July 15, 2020	Notice of change of interests of substantial holder – 15 July 2020	pdf	124 KB
July 13, 2020	Notice of change of interests of substantial holder – 13 July 2020	pdf	621 KB
July 9, 2020	Notice of change of interests of substantial holder – 9 July 2020	pdf	620 KB
July 8, 2020	Notice of change of interests of substantial holder – 8 July 2020	pdf	620 KB
July 7, 2020	Notice of change of interests of substantial holder – 7 July 2020	pdf	1,014 KB
July 6, 2020	Notice of change of interests of substantial holder – 6 July 2020	pdf	125 KB
July 2, 2020	Appendix 2A and Section 708A(5) Cleansing Notice- July 2020	pdf	379 KB
July 1, 2020	Proposed Issue of Securities – July 2020	pdf	28 KB
July 1, 2020	Response to ASX Price Query – July 2020	pdf	1,003 KB
June 9, 2020	Notice of change of interests of substantial holder – 9 June 2020	pdf	127 KB
May 28, 2020	Notice of change of interests of substantial holder – 28 May 2020	pdf	140 KB
May 27, 2020	Notice of change of interests of substantial holder – 27 May 2020	pdf	123 KB
May 26, 2020	Appendix 2A and Section 708A(5) Cleansing Notice- May 2020	pdf	353 KB
May 25, 2020	Proposed Issue of Securities – May 2020	pdf	29 KB
May 21, 2020	Alterity Presents Data on ATH434 to the American Academy of Neurology – May 2020	pdf	204 KB
April 22, 2020	NASDAQ Temporary Relief – April 2020	pdf	194 KB
March 27, 2020	Appendix 2A – March 2020	pdf	383 KB
March 26, 2020	Proposed Issue of Securities – March 2020	pdf	28 KB
February 7, 2020	Non-Compliance Notice Regarding Minimum Bid Requirement	pdf	214 KB
January 21, 2020	Appendix 3B – January 2020	pdf	343 KB

December 11, 2019	Upcoming release of warrants from voluntary escrow December 2019	pdf	149 KB
November 26, 2019	Results of AGM 2019	pdf	169 KB
November 26, 2019	Chairman’s Address 2019 AGM	pdf	156 KB
November 22, 2019	Appendix 3B – November 2019	pdf	344 KB
October 25, 2019	Notice of AGM 2019	pdf	1 MB
September 2, 2019	Alterity filed Form 20-F and XBRL data with the SEC 2019	pdf	158 KB
August 20, 2019	Notice of Change of Interests of Substantial Holder August 2019	pdf	1,006 KB
August 5, 2019	Upcoming Release of Shares from Voluntary Escrow – August 2019	pdf	266 KB
August 1, 2019	Appendix 3B – New Issue Announcement – August 2019	pdf	350 KB
August 1, 2019	Quarterly Cash Flow Report – June 2019	pdf	373 KB
July 29, 2019	Successful Completion of Phase 1 Clinical Trial – July 2019	pdf	201 KB
June 12, 2019	Alterity presents at the American Academy of Neurology	pdf	238 KB
June 12, 2019	Alterity commences US investor meetings 2019	pdf	205 KB
June 12, 2019	Becoming a substantial shareholder 2019	pdf	2 MB
June 12, 2019	Form 603 Notice lodged by Bank of New York Mellon	pdf	205 KB
June 12, 2019	Alterity Thereapeutics commences US investor meetings2019	pdf	205 KB
June 4, 2019	Notice of Ceasing to be a Substantial Holder ATH – June 2019	pdf	90 KB
June 4, 2019	Alterity Therapeutics Investor Presentation to Finance News Network Conference – Jun 2019	pdf	1 MB
May 23, 2019	Prospectus filed pursuant to SEC Rule 424(b)(3) – May 2019	pdf	433 KB
May 20, 2019	Upcoming Release of Shares from Escrow – May 2019	pdf	203 KB
May 14, 2019	Form F-3 – May 2019	pdf	857 KB
April 10, 2019	Becoming A Substantial Shareholder Alterity – Apr 2019	pdf	723 KB
April 10, 2019	Appendix 3X – Initial Directors Interest Notice DS – Apr 2019	pdf	125 KB
April 10, 2019	Appendix 3X – Initial Directors Interest Notice TE – Apr 2019	pdf	126 KB
April 10, 2019	Appendix 3Z – Final Directors Interest Notice IS – Apr 2019	pdf	127 KB
April 10, 2019	Appendix 3Z – Final Directors Interest Notice GM – Apr 2019	pdf	127 KB
April 10, 2019	Notice of Initial Substantial Holder Life Biosciences – Apr 2019	pdf	1 MB
March 21, 2019	Appendix 3B – Mar 2019	pdf	318 KB
March 6, 2019	Notice of General Meeting – Apr 2019	pdf	3 MB
March 5, 2019	Notice of General Meeting and Explanatory Memorandum – Mar 2019	pdf	3 MB
January 9, 2019	Notice of ceasing to be a substantial holder MUFG – Jan 2019	pdf	165 KB
January 9, 2019	Notice of Ceasing to be a Substantial Holder MS – Jan 2019	pdf	263 KB
January 7, 2019	Prana Biotechnology BSC Presentation – Jan 2019	pdf	1 MB

February 10, 2019	Appendix 3B – Cleansing Notice – Feb 2018	pdf	362 KB
January 7, 2019	Form 603 – Notice of Initial Substantial Holder Morgan Stanley – Jan 2018	pdf	543 KB
January 7, 2019	Form 603 – Notice of Initial Substantial Holder MUFG – Jan 2018	pdf	457 KB
January 7, 2019	Appendix 3B – Jan 2018	pdf	955 KB
December 23, 2018	PBT Trading Halt – Dec 2018	pdf	459 KB
December 4, 2018	Form S-8 Dec 2018	pdf	271 KB
November 19, 2018	Appendix 3B – Nov 2018	pdf	940 KB
November 19, 2018	Appendix 3Y Change of Director’s Interest Notice – Nov 2018	pdf	456 KB
November 16, 2018	Results of AGM 2018	pdf	186 KB
November 16, 2018	AGM Presentation – Nov 2018	pdf	621 KB
October 16, 2018	Notice of AGM – Oct 2018	pdf	849 KB
July 16, 2018	Appendix 3B and 708A Notice – Jul 2018	pdf	248 KB
June 27, 2018	Investor Presentation – Jun 2018	pdf	5 MB
January 22, 2018	Appendix 3B – Jan 2018	pdf	809 KB

December 22, 2017	Appendix 3Y Change of Director’s Interest PM – Dec 2017	pdf	532 KB
December 22, 2017	Appendix 3Y – Change of Director’s Interest LG – Dec 2017	pdf	532 KB
December 22, 2017	Appendix 3Y – Change of Director’s Interest GM – Dec 2017	pdf	533 KB
December 22, 2017	Appendix 3Y – Change of Director’s Interest BM – Dec 2017	pdf	533 KB
December 22, 2017	Appendix 3Y Change of Director’s Interest GPK – Dec 2017	pdf	534 KB
December 19, 2017	Appendix 3B – Dec 2017	pdf	810 KB
November 17, 2017	AGM Presentation 2017	pdf	980 KB
November 17, 2017	Results of AGM 2017	pdf	92 KB
November 9, 2017	Form 6-K Nov 2017	pdf	70 KB
November 9, 2017	Prospectus Supplement – Nov 2017	pdf	149 KB
October 16, 2017	Notice of AGM – Oct 2017	pdf	8 MB
October 11, 2017	Form F-3 Oct 2017	pdf	255 KB
September 26, 2017	Change of Address -Sept 2017	pdf	619 KB
June 26, 2017	Change of Address – June 2017	pdf	366 KB
June 7, 2017	Appendix 3B – Jun 2017	pdf	814 KB

Investor Centre
Archive

Investor Resources

Investor presentations

ASX Announcements

Financial reports

Corporate governance

News

Quarterly Cash Flow Report

ATH434 protects brain cells and improves motor function

Alterity CEO David Stamler presents to US investors at the HC Wainwright Global Life Science Conference

Alterity to present at the 7th International Congress of Multiple System Atrophy

Alterity Half Year Results and Investor Webcast Notification

Alterity announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson’s disease clinical trials

Quarterly Cash Flow Report

New hope in global fight against antibiotic resistant superbugs

Alterity participates in world’s largest virtual healthcare conference JP Morgan

Dr David Stamler appointed CEO

Alterity and UniQuest to reverse bacterial resistance to antibiotics

Alterity presents at Finance News Network investor event

AGM 2020 Presentation

Chairman’s Address to Shareholders 2020 Annual General Meeting

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study

Alterity completes Placement Tranche 1 raising $10M

Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology

Alterity receives a $4.8 million R&D Tax Incentive Refund

European Commission approves Orphan Designation for Alterity’s lead drug candidate

Alterity presents clinical data on PBT434 at the 2019 MDS Congress

Alterity Therapeutics to Present at the Janney Healthcare Conference in New York

Quarterly Cash Flow Report

Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial

Alterity Therapeutics talks to Finance News Network

Receive news from Alterity Therapeutics

May 10, 2019	Prana Completes Ratio Change on NASDAQ – Mar 2016	pdf	377 KB
November 17, 2016	Results of AGM – Nov 2017	pdf	65 KB
October 14, 2016	Notice of AGM – Oct 2016	pdf	9 MB
October 14, 2016	Prospectus Supplement – Oct 2016	pdf	201 KB
October 14, 2016	Form-6k Oct 2016	pdf	263 KB
April 22, 2016	Prana Presents at World Orphan Drug Congress – Apr 2016	pdf	3 MB
March 29, 2016	PBT Completes Ratio Change on NASDAQ – Mar 2016	pdf	377 KB

March 10, 2016	ADR Rati Change – Mar 2016	pdf	95 KB
November 16, 2015	AGM Presentation – 2015	pdf	645 KB
November 13, 2015	Results of AGM – 2015	pdf	68 KB
November 12, 2015	AGM Presentation 2015	pdf	786 KB
October 12, 2015	Notice of AGM – 2015	pdf	575 KB
August 27, 2015	Annual Report and 4E – Jun 2015	pdf	8 MB
August 26, 2015	Appendix 4G – Jun 2015	pdf	202 KB
June 2, 2015	Appendix 3Y – Change of Directors Interest – Jun 2015	pdf	52 KB
May 27, 2015	Appendix 3B and s708A Notice – May 2015	pdf	559 KB
April 28, 2015	PBT2 Recommended for Orphan Designation Europe – Apr 2015	pdf	139 KB
February 18, 2015	Appendix 3B and s708A Notice – Feb 2015	pdf	169 KB
February 13, 2015	FDA notification – Feb 2015	pdf	378 KB

November 26, 2014	Form 6-K Nov 2014	pdf	41 KB
November 26, 2014	Prospectus Supplement – Nov 2014	pdf	253 KB
November 19, 2014	Results of AGM 2014 – Nov 2014	pdf	49 KB
November 19, 2014	Form F-6 Nov 2014	pdf	669 KB
November 18, 2014	Form F-3 Nov 2014	pdf	213 KB
November 11, 2014	AGM Conference Call Access – Nov 2014	pdf	239 KB
October 13, 2014	Appendix 3B – Oct 2014	pdf	165 KB
October 13, 2014	Notice of AGM – Oct 2014	pdf	462 KB
July 28, 2014	Form F-3 Jul 2014	pdf	108 KB
May 19, 2014	Appendix 3B and 708A notice – May 2014	pdf	218 KB
May 19, 2014	Appendix 3B – Jan 2014	pdf	200 KB
May 19, 2014	Response to ASX inquiry – Feb 2014	pdf	212 KB
May 19, 2014	Appendix B – Feb 2014	pdf	203 KB
May 19, 2014	Trading Halt – Feb 2014	pdf	89 KB
May 19, 2014	Prana admitted to S&P – Mar 2014	pdf	129 KB
May 19, 2014	Appendix 3B – Mar 2014	pdf	196 KB
May 19, 2014	Trading halt – Mar 2014	pdf	78 KB
May 19, 2014	Compan’s Request for Trading Halt – Mar 2014	pdf	60 KB
May 19, 2014	Movement Expert Joins – May 14	pdf	125 KB
May 19, 2014	Interview IRA – May 2014	pdf	124 KB
May 13, 2014	Movement Disorders Expert Joins Prana Board – May 2014	pdf	122 KB
April 28, 2014	Prana Biotechnology Announces Preliminary Result of Alzheimer’s Trial – Apr 2014	pdf	835 KB
April 28, 2014	Prana 3B – April 2014	pdf	224 KB
April 1, 2014	Exercise of Options Form – Apr 2014	pdf	50 KB
March 6, 2014	S&P Dow Jones – Mar 2014	pdf	100 KB
March 6, 2014	Prana Alzheimers Disease Treatment Validated – Mar 6	pdf	746 KB
March 4, 2014	Prana Presents at 34th Cowen Healthcare Conference – Mar 2014	pdf	129 KB
March 4, 2014	Form 6K – Feb 2014	pdf	134 KB
March 4, 2014	Appendix 3B and Section 708A Notice – Feb 2014	pdf	196 KB
March 4, 2014	Commentary on Half Year Results – Mar 2014	pdf	93 KB
February 18, 2014	Prana REACH2HD Trial Results Conference Call Alert – Feb 2014	pdf	445 KB
February 18, 2014	Prana Announces Successful Phase 2 Results in Huntington Disease Trial – Feb 2018	pdf	942 KB
January 23, 2014	Prana Commences US Investor Roadshow – Jan 2014	pdf	895 KB

September 9, 2013	Appendix 3B – Oct 2013	pdf	288 KB
September 9, 2013	Appendix 3B – May 2013	pdf	101 KB
September 9, 2013	Appendix 3B – Jan 2013	pdf	101 KB
September 9, 2013	Appendix 3B – Feb 2013	pdf	101 KB
September 9, 2013	Appendix 3B – Dec 2013	pdf	100 KB
July 17, 2013	Prana Share Purchase Plan Closed – May 2013	pdf	30 KB
July 17, 2013	Share Purchase Plan 2013 Offer Document – Jul 2013	pdf	220 KB
July 17, 2013	Notice of Ceasing to be a Substantial Shareholder – July 2013	pdf	32 KB

September 9, 2013	Appendix 4E – Jun 2012	pdf	137 KB
September 9, 2013	Appendix 3B and Section 708a – 26 Sept 2012	pdf	288 KB
September 9, 2013	Appendix 3B and Section 708a – 17 Sept 2012	pdf	288 KB
September 9, 2013	Appendix 3B and Section 708a – 3 Sept 2012	pdf	288 KB
September 9, 2013	Appendix 3B and Section 708 – May 25 2012	pdf	101 KB
September 9, 2013	Appendix 3B and Section 708a – Mar 21 2012	pdf	102 KB
September 9, 2013	Appendix 3B and Section 708a – Jan 17 2012	pdf	101 KB
September 9, 2013	Appendix 3B and Section 708a – Jan 9 2012	pdf	101 KB
September 9, 2013	Appendix 3B and Section 708a – Feb 16 2012	pdf	101 KB
September 9, 2013	Appendix 3B and section 708a – 10 Feb 2012	pdf	101 KB
September 9, 2013	Appendix 3B and Section 708a – 1 Feb 2012	pdf	101 KB
September 9, 2013	Appendix 3B and Section 708a- 27 Aug 2012	pdf	288 KB
July 17, 2013	Change of Directors Interest Notice – Jan 2012	pdf	76 KB
July 17, 2013	Appendix 3B and Section 708A – 9 Jan 2012	pdf	101 KB
July 17, 2013	Notice Under Section 708A – 10 Jan 2012	pdf	33 KB
July 17, 2013	Notice Under Section 708A – 11 Jan 2012	pdf	33 KB
July 17, 2013	Appendix 3B and Section 708A – Jan 2012	pdf	101 KB
July 17, 2013	Appendix 3B and Section 708A – Jan 30 2012	pdf	101 KB
July 17, 2013	Appendix 3B and Section 708A – 1 Feb 2012	pdf	101 KB
July 17, 2013	Appendix 3B and Section 708A – 7 Feb 2012	pdf	101 KB
July 17, 2013	Notice Under Section 708A – 8 Feb 2012	pdf	33 KB
July 17, 2013	Notice Under Section 708A – 9 Feb 2012	pdf	33 KB
July 17, 2013	Notice Under Section 708A – 9 Feb 2012	pdf	33 KB
July 17, 2013	Appendix 3B and Section 708A Notice – 10 Feb 2012	pdf	101 KB
July 17, 2013	Appendix 3B and Section 708A – 16 Feb 2012	pdf	101 KB
July 17, 2013	Appendix 3B and Section 708A – 29 Mar 2012	pdf	102 KB
July 17, 2013	Notice of General Meeting – Apr 2012	pdf	117 KB
July 17, 2013	Change of Directors Interest Notice – Apr 2012	pdf	76 KB
July 17, 2013	Results of General Meeting – May 2012	pdf	44 KB
July 17, 2013	Appendix 3B and Section 708a Notice – 21 May 2012	pdf	101 KB
July 17, 2013	Appendix 3B and Section 708a Notice – 25 May 2012	pdf	101 KB
July 17, 2013	Appendix 3B and Section 708A – 27 Aug 2012	pdf	288 KB
July 17, 2013	Appendix 4E – June 2012	pdf	137 KB
July 17, 2013	Appendix 3B – Sept 2012	pdf	288 KB
July 17, 2013	Appendix 3B and Section 708a Notice – 17 Sept 2012	pdf	288 KB
July 17, 2013	Appendix 3B and Section 708a Notice – 26 Sept 2012	pdf	288 KB
July 17, 2013	Appendix 3B and Section 708a Notice – 10 Oct 2012	pdf	288 KB
July 17, 2013	Change in Substantial Holding Baywick – Oct 2012	pdf	115 KB
July 17, 2013	Change in Substantial Holding Jagen – Oct 2012	pdf	327 KB
July 17, 2013	Notice of AGM – Nov 2012	pdf	430 KB
July 17, 2013	2012-12-12-Change-of-Directors-Interest-Notice	pdf	122 KB
July 17, 2013	2012-12-12-AGM-Presentation	pdf	94 KB
July 17, 2013	2012-12-12-Results-of-AGM	pdf	49 KB
July 17, 2013	2012-12-22-Appendix-3B-Notice-708A	pdf	100 KB

February 10, 2014	Prana-Appendix-3B-708A-2011-Sep-21	pdf	101 KB
February 10, 2014	Prana-Appendix-3B-708A-2011-Sep-19	pdf	101 KB
February 10, 2014	Prana-Appendix-3B-708A-2011-Nov-25	pdf	100 KB
February 10, 2014	Prana-Appendix-3B-708A-2011-Nov-21	pdf	100 KB
February 10, 2014	Prana-Appendix-3B-708A-2011-Mar	pdf	101 KB
February 10, 2014	Prana-Appendix-3B-708A-2011-Jul	pdf	103 KB
February 10, 2014	Prana-Appendix-3B-708A-2011-Apr	pdf	102 KB
September 9, 2013	Prana-Appendix-3B-708A-2011-Nov-21	pdf	100 KB
September 9, 2013	Prana-Form-F3-2011-Apr	pdf	120 KB
September 9, 2013	Appendix 4E – Jun 2011	pdf	121 KB
September 9, 2013	Appendix 3B – Dec 2011	pdf	279 KB
September 9, 2013	Appendix 3B and Section 708A – 21 Sept 2011	pdf	101 KB
September 9, 2013	Appendix 3B and Section 708A – 19 Sept 2011	pdf	101 KB
September 9, 2013	Appendix 3B and Section 708A – 25 Nov 2011	pdf	100 KB
September 9, 2013	Appendix 3B and Section 708A – 4 Mar 2011	pdf	101 KB
September 9, 2013	Appendix 3B and Section 708A – 1 Jul 2011	pdf	103 KB
September 9, 2013	Appendix 3B and Section 708A – 8 Apr 2011	pdf	102 KB

February 10, 2014	2010-11-26-Results-of-AGM	pdf	30 KB
February 10, 2014	2010-08-17-Results-of-General-meeting	pdf	27 KB
February 10, 2014	Prana-Appendix-3B-708A-2010-Sep	pdf	118 KB
February 10, 2014	Prana-Appendix-3B-708A-2010-Oct	pdf	102 KB
February 10, 2014	Prana-Appendix-3B-708A-2010-Nov-04	pdf	102 KB
February 10, 2014	Prana-Appendix-3B-708A-2010-Mar	pdf	108 KB
February 10, 2014	Prana-Appendix-3B-708A-2010-Jun	pdf	125 KB
February 10, 2014	Prana-Appendix-3B-708A-2010-Jul	pdf	123 KB
September 9, 2013	Prana-Appendix-3B-708A-2010-Mar	pdf	108 KB
September 9, 2013	Appendix 4E – Jun 2010	pdf	200 KB
September 9, 2013	Appendix 3Y – Nov 2010	pdf	153 KB
September 9, 2013	Appendix 3Y – Dec 2010	pdf	53 KB
September 9, 2013	Appendix 3X – Jan 2010	pdf	43 KB
September 9, 2013	Appendix 3B and Section 708A – 4 Nov 2010	pdf	100 KB
September 9, 2013	Appendix 3B – Sept 2010	pdf	118 KB
September 9, 2013	Appendix 3B and Section 708A – 8 Oct 2010	pdf	102 KB
September 9, 2013	Appendix 3B and Section 708A – 4 Nov 2010	pdf	102 KB
September 9, 2013	Appendix 3B and Section 708A – May 2010	pdf	108 KB
September 9, 2013	Appendix 3B and Section 708A – 8 Jun 2010	pdf	125 KB
September 9, 2013	Prana Appendix 3B and Section 708A – 19 Jul 2010	pdf	123 KB

August 27, 2013	Appendix 4C – Sept 2007	pdf	41 KB
August 27, 2013	Appendix 4C – Mar 2007	pdf	89 KB
August 27, 2013	Appendix 4C – Jun 2007	pdf	41 KB
August 26, 2013	Form-6K Mar 2007	pdf	1 MB

August 26, 2013	Form 6K – Mar 2006	pdf	1 MB
August 26, 2013	Appendix 4D – Dec 2006	pdf	584 KB

August 26, 2013	Form 6K – Mar 2005	pdf	564 KB
August 26, 2013	Appendix 4D – Dec 2005	pdf	139 KB

January 29, 2021	Appendix 4C- December 2020	pdf	339 KB
October 30, 2020	Appendix 4C- September 2020	pdf	354 KB
September 16, 2020	Form 20-F 2020	pdf	2 MB
September 9, 2020	Appendix 4G Ended 30 June 2020	pdf	374 KB
September 9, 2020	Annual Report 2020	pdf	2 MB
August 31, 2020	Appendix 4E Year ended 30 June 2020	pdf	454 KB
July 30, 2020	Appendix 4C – June 2020	pdf	384 KB
April 30, 2020	Appendix 4C – March 2020	pdf	346 KB
February 28, 2020	Form 6-K Feb 2020	pdf	233 KB
February 28, 2020	Appendix 4D 2019	pdf	410 KB
January 31, 2020	Appendix 4C – December 2019	pdf	372 KB

October 30, 2019	Appendix 4C – September 2019	pdf	346 KB
September 2, 2019	Form 20-F 2019	pdf	828 KB
August 30, 2019	Appendix 4G FY Ended 2019_06_30	pdf	341 KB
August 30, 2019	Annual Report 2019	pdf	1 MB
August 1, 2019	Appendix 4C – June 2019	pdf	151 KB
May 13, 2019	Form-6-K-2019_03_01	pdf	400 KB
April 16, 2019	Appendix 4C – Mar 2019	pdf	161 KB
February 28, 2019	Form 6-K – Mar 2019	pdf	400 KB
February 28, 2019	Appendix 4D 2018	pdf	217 KB
January 31, 2019	Appendix 4C – Dec 2018	pdf	234 KB

May 13, 2019	Form 6-K Feb 2018	pdf	148 KB
October 30, 2018	Appendix 4C – Sept 2018	pdf	170 KB
September 3, 2018	Form 20F – 2018	pdf	2 MB
August 31, 2018	Appendix 4G FY Ended 2018_06_30	pdf	123 KB
August 31, 2018	Annual Report 2018	pdf	2 MB
July 30, 2018	Appendix 4C – Jun 2018	pdf	262 KB
May 7, 2018	Appendix 4C – Mar 2018	pdf	263 KB
March 4, 2018	Form 6-K Feb 2018	pdf	148 KB

June 7, 2019	Appendix 4C – Dec 2017	pdf	700 KB
May 13, 2019	Form 6-K 2017	pdf	70 KB
March 4, 2018	Appendix 4D – Dec 2017	pdf	275 KB
January 30, 2018	Appendix 4C – December 2017	pdf	700 KB
October 30, 2017	Appendix 4C – Sept 2017	pdf	699 KB
September 1, 2017	Form 20-F2017	pdf	822 KB
August 31, 2017	Annual Report 2017	pdf	2 MB
August 1, 2017	Appendix 4C – Jun 2017	pdf	698 KB
May 10, 2017	Appendix 4C – Mar 2017	pdf	52 KB
February 24, 2017	Form 6-K Feb 2017	pdf	221 KB

June 7, 2019	Appendix 4E – June 2016	pdf	586 KB
February 24, 2017	Appendix 4D – 2016	pdf	282 KB
January 30, 2017	Appendix 4C – Dec 2016	pdf	265 KB
October 30, 2016	Appendix 4C – Sept 2016	pdf	265 KB
October 4, 2016	Form 20-F2016	pdf	907 KB
October 2, 2016	Annual Report 2016	pdf	3 MB
July 26, 2016	Appendix 4C – June 2016	pdf	248 KB
April 29, 2016	Appendix 4C – Mar 2016	pdf	179 KB
February 25, 2016	Form 6-K Feb 2016	pdf	170 KB

February 25, 2016	Appendix 4D – 2015	pdf	1 MB
January 29, 2016	Appendix 4C – Dec 2015	pdf	182 KB
October 30, 2015	Appendix 4C – Sept 2015	pdf	179 KB
August 26, 2015	Form 20-F2015	pdf	836 KB
August 26, 2015	Annual Report 2015	pdf	8 MB
July 27, 2015	Appendix 4C – Jun 2015	pdf	55 KB
April 28, 2015	Appendix 4C – Mar 2015	pdf	76 KB
February 24, 2015	Form 6-K 2015	pdf	132 KB

February 24, 2015	Appendix 4D – 2014	pdf	2 MB
January 30, 2015	Appendix 4C – Dec 2014	pdf	55 KB
November 19, 2014	Appendix 4C – Mar 2014	pdf	71 KB
November 13, 2014	Appendix 4C – Sept 2014	pdf	60 KB
October 1, 2014	Annual Report 2014	pdf	8 MB
September 1, 2014	Appendix 4E – 2014	pdf	407 KB
July 31, 2014	Appendix 4C – Jun 2014	pdf	81 KB

June 7, 2019	Form 20-F2013	pdf	2 MB
April 28, 2014	Appendix 4C – Dec 2013	pdf	61 KB
March 4, 2014	Appendix 4D – 2013	pdf	2 MB
February 9, 2014	Annual Report 2013	pdf	2 MB
November 27, 2013	Appendix 4C – Sept 2013	pdf	64 KB
August 27, 2013	Appendix 4C – Mar 2013	pdf	60 KB
August 27, 2013	Appendix 4C – Jun 2013	pdf	61 KB
August 26, 2013	Form 6K – Feb 2013	pdf	118 KB

June 7, 2019	Appendix 4D – Dec 2012	pdf	1 MB
June 7, 2019	Appendix 4C – Sept 2012	pdf	149 KB
August 27, 2013	Appendix 4C – Mar 2012	pdf	59 KB
August 27, 2013	Appendix 4C – Jun 2012	pdf	59 KB
August 27, 2013	Appendix 4C – Dec 2012	pdf	59 KB
August 26, 2013	Annual Report 2012	pdf	4 MB
August 26, 2013	Form 20-F2012	pdf	2 MB

June 7, 2019	Appendix 4C – Dec 2011	pdf	59 KB
June 7, 2019	Appendix 4C – Sept 2011	pdf	59 KB
June 7, 2019	Appendix 4C – Mar 2011	pdf	59 KB
September 9, 2013	Form 6K- May 2011	pdf	149 KB
September 9, 2013	Form 6K – Jul 2011	pdf	190 KB
August 27, 2013	Appendix 4C-June 2011	pdf	59 KB
August 26, 2013	Appendix 4D -Dec 2011	pdf	855 KB
August 26, 2013	Annual Report 2011	pdf	3 MB
August 26, 2013	Form 20-F 2011	pdf	664 KB

June 7, 2019	Form 20F – Jun 2010	pdf	1 MB
June 7, 2019	Form 6-K Feb 2010	pdf	99 KB
June 7, 2019	Appendix 4C – Sept 2010	pdf	59 KB
June 7, 2019	Appendix 4C – Dec 2010	pdf	59 KB
August 27, 2013	Appendix 4C- Mar 2010	pdf	66 KB
August 27, 2013	Appendix 4C – Jun 2010	pdf	63 KB
August 26, 2013	Appendix 4D – Dec 2010	pdf	983 KB
August 26, 2013	Annual Report 2010	pdf	2 MB

June 7, 2019	Form 20F – 2009	pdf	1 MB
June 7, 2019	Form 6-K Feb 2009	pdf	107 KB
August 27, 2013	Appendix 4C – Sept 2009	pdf	122 KB
August 27, 2013	Appendix 4C – Mar 2009	pdf	79 KB
August 27, 2013	Appendix 4C – Jun 2009	pdf	77 KB
August 27, 2013	Appendix 4C – Dec 2009	pdf	65 KB
August 26, 2013	Appendix 4D – Dec 2009	pdf	1 MB
August 26, 2013	Annual Report 2009	pdf	2 MB

June 7, 2019	Form 20-F 2008	pdf	6 MB
June 7, 2019	Appendix 4C – December 2008	pdf	79 KB
August 27, 2013	Appendix 4C – Sept 2008	pdf	78 KB
August 27, 2013	Appendix 4C – Mar 2008	pdf	77 KB
August 27, 2013	Appendix 4C – Jun 2008	pdf	76 KB
August 26, 2013	Form 6-K Feb 2008	pdf	152 KB
August 26, 2013	Appendix 4D – Dec 2008	pdf	864 KB
August 26, 2013	Annual Report 2008	pdf	1 MB

June 7, 2019	Form 20-F 2007	pdf	15 MB
June 7, 2019	Appendix 4C – Dec 2007	pdf	76 KB
August 26, 2013	Appendix 4D – Dec 2007	pdf	578 KB
August 26, 2013	Annual Report 2007	pdf	3 MB

June 7, 2019	Appendix 4C – Sept 2006	pdf	76 KB
June 7, 2019	Form 20-F 2006	pdf	935 KB
August 26, 2013	Annual Report 2006	pdf	2 MB

June 7, 2019	Form 20-F 2005	pdf	9 MB
August 27, 2013	Appendix 4C – Dec 2005	pdf	136 KB
August 26, 2013	Annual Report 2005	pdf	2 MB

June 7, 2019	Form 20-F 2004	pdf	403 KB
August 27, 2013	Appendix 4C – Sept 2004	pdf	30 KB
August 27, 2013	Appendix 4C – March 2004	pdf	25 KB
August 27, 2013	Prana-Appendix-4C-2004-Jun	pdf	25 KB
August 27, 2013	Prana-Appendix-4C-2004-Dec	pdf	30 KB
August 26, 2013	Annual Report 2004	pdf	573 KB

June 7, 2019	Form 20-F 2003	pdf	4 MB
August 26, 2013	Appendix 4D – Dec 2003	pdf	84 KB
August 26, 2013	Annual Report 2003	pdf	869 KB

May 4, 2021	Corporate Governance Statement 2020	pdf	205 KB
November 23, 2020	2018 ADS Plan (as amended)	pdf	100 KB
November 23, 2020	2004 ASX Plan (as amended)	pdf	52 KB
November 18, 2020	ATH – Constitution (Amended)	pdf	433 KB
April 29, 2020	Board Charter	pdf	1 MB
May 15, 2019	Whistle Blower Policy	pdf	320 KB
May 15, 2019	Securities Trading Policy	pdf	343 KB
May 15, 2019	Diversity Policy	pdf	197 KB